Volume 14, Number 10—October 2008
Research
Prophylaxis after Exposure to Coxiella burnetii
Figure 3
![Decision tree for 100,000 pregnant women based on an assumption of an aerosolized, point source, overt attack with Coxiella burnetii (postexposure prophylaxis [PEP] with 160/800 mg trimethoprim-sulfamethoxazole 2×/d for duration of pregnancy, assuming 82% efficacy and 100% exposure.) PEP-related adverse events are not included in this figure. The “No PEP” segment of the tree contains the same branches and nodes as seen in the “With PEP” section, but uses different probabilities for certain varia](/eid/images/08-0576-F3.jpg)
Figure 3. Decision tree for 100,000 pregnant women based on an assumption of an aerosolized, point source, overt attack with Coxiella burnetii (postexposure prophylaxis [PEP] with 160/800 mg trimethoprim-sulfamethoxazole 2×/d for duration of pregnancy, assuming 82% efficacy and 100% exposure.) PEP-related adverse events are not included in this figure. The “No PEP” segment of the tree contains the same branches and nodes as seen in the “With PEP” section, but uses different probabilities for certain variables. *The outcome of the unborn child is included in pregnant women illness estimates: low birth weight newborns were included in “Total Illness” estimates, and abortions/newborn deaths were included in all 3 outcome categories. QFS, Q fever fatigue syndrome.